8 mg/3 mL of liquid solution. There’s one pen with this strength, and it delivers 2-mg doses. Typically, your doctor will start you on a low dosage. Then, they’ll adjust it over time to reach ...

AstraZeneca Plc's AZN Bydureon BCise (exenatide 2 mg prolonged-release suspension for injection) is indicated for type-2 diabetes. Novo Nordisk A/S' NVO semaglutide is approved as Ozempic and ...

Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.